1

1 The Healthy Brain Initiative (HBI): A prospective cohort study protocol

- 2 Lilah M. Besser^a, Stephanie Chrisphonte^a, Michael J. Kleiman^a, Deirdre O'Shea^a, Amie
- 3 Rosenfeld, DPT^a, Magdalena Tolea^a, James E. Galvin^a
- ^a Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller
- 5 School of Medicine, 7700 Camino Real Suite 200, Boca Raton, FL 33433
- 6

7 Abstract

8 **Background**: The Health Brain Initiative (HBI), established by University of Miami's

9 Comprehensive Center for Brain Health (CCBH), follows racially/ethnically diverse older adults

10 without dementia living in South Florida. With dementia prevention and brain health promotion

11 as an overarching goal, HBI will advance scientific knowledge by developing novel assessments

12 and non-invasive biomarkers of Alzheimer's disease and related dementias (ADRD), examining

13 additive effects of sociodemographic, lifestyle, neurological and biobehavioral measures, and

employing innovative, methodologically advanced modeling methods to characterize ADRD risk

15 and resilience factors and transition of brain aging.

16 Methods: HBI is a longitudinal, observational cohort study that will follow 500 deeply-

17 phenotyped participants annually to collect, analyze, and store clinical, cognitive, behavioral,

functional, genetic, and neuroimaging data and biospecimens. Participants are \geq 50 years old;

19 have no, subjective, or mild cognitive impairment; have a study partner; and are eligible to

20 undergo magnetic resonance imaging (MRI). Recruitment is community-based including

advertisements, word-of-mouth, community events, and physician referrals. At baseline,

22 following informed consent, participants complete detailed web-based surveys (e.g.,

23 demographics, health history, risk and resilience factors), followed by two half-day visits which

include neurological exams, cognitive and functional assessments, an overnight sleep study,

and biospecimen collection. Structural and functional MRI is completed by all participants and a

26 subset also consent to amyloid PET imaging. Annual follow-up visits repeat the same data and

- 27 biospecimen collection as baseline, except that MRIs are conducted every other year after
- 28 baseline.
- 29 **Ethics and expected impact**: HBI has been approved by the University of Miami Miller School
- 30 of Medicine Institutional Review Board. Participants provide informed consent at baseline and
- 31 are re-consented as needed with protocol changes. Data collected by HBI will lead to
- 32 breakthroughs in developing new diagnostics and therapeutics, create comprehensive
- diagnostic evaluations, and provide the evidence base for precision medicine approaches to
- 34 dementia prevention with individualized treatment plans.

3

35 INTRODUCTION

36 Alzheimer's disease and related dementias (ADRD) affect approximately 55 million individuals worldwide, and the prevalence is projected to rise with the expected surge in the population of 37 older adults over the next few decades (1). ADRD are neurodegenerative diseases that result in 38 39 cognitive and functional decline, with initial symptoms varying based on etiology. For example, Alzheimer's disease (AD), which involves the accumulation of amyloid plagues and tau tangles 40 41 throughout the brain, typically begins with episodic memory problems experienced during older age (e.g. \geq 65 years) (2). In contrast, Lewy body dementia (LBD), which is associated with the 42 43 accumulation of alpha-synuclein protein or Lewy bodies in the brain, usually presents as having motor symptoms, cognitive fluctuations, rapid eye movement (REM) sleep behavior disorder, 44 and/or visual hallucinations starting at age 50 or older (3). Some recent advances have been 45 made in clinical trials, such as monoclonal antibody treatments (e.g., aducanumab, lecanumab, 46 47 donanemab), which have been shown to remove amyloid plagues and slow cognitive decline 48 among individuals with early AD (4). These monoclonal antibody treatments have been associated with amyloid-related imaging abnormalities and therefore require careful monitoring 49 with serial Magnetic Resonance Imaging (MRI) (5) that is costly, time-consuming, and 50 51 burdensome. However, no treatments are presently available to prevent incipient ADRD. Thus, while much research effort remains directed at drug development focused on removing ADRD 52 pathology to slow or halt cognitive decline amongst symptomatic individuals, there is still a great 53 54 need for studies to identify at-risk individuals and develop primary and secondary prevention 55 strategies.

56

Older age, familial dominant genetic mutations (e.g., APP, PSEN1, PSEN2 for AD), and genetic
risk factors (e.g., ≥1 apolipoprotein e4 allele) contribute significantly to an individual's
vulnerability toward developing ADRD (6). Beyond these non-modifiable risk factors, 12
modifiable risk factors were identified by the Lancet Commission in 2020 as significant

4

contributors to dementia risk based on a review of the extant literature (7). These risk factors, 61 62 which were estimated to account for approximately 40% of dementias worldwide, include less education, smoking, obesity, hearing impairment, depression, physical inactivity, hypertension, 63 diabetes, low social contact, traumatic brain injury (TBI), alcohol consumption, and air pollution 64 65 exposure. The estimates of population attributable fraction (PAF) from the Lancet commission have been modified over time (from 2017 (8) to 2020 (7)) to add TBI, air pollution, and alcohol 66 use), and will likely be modified again as evidence accumulates for additional risk factors that 67 have not been adequately studied to date. In addition, the PAF estimates were based on a 68 69 sample in the United Kingdom, which might have different risk factors that regions with differing diversity by factors such as racial/ethnic group. Altogether, the 12 identified risk factors 70 represent an initial list of important dementia risk factors that will likely be expanded based on 71 72 evidence from new studies and more diverse cohorts.

73

74 Recently, clinical and epidemiological studies have shifted to not only focus on risk factors for developing dementia, but also on the unique factors that impart resistance against the 75 development of ADRD neuropathology or resilience against cognitive decline in the face of 76 77 underlying neuropathology (9). This shift in orientation parallels an increased research interest in brain health, which is the "preservation of optimal brain integrity and mental and cognitive 78 function at a given age in the absence of overt brain diseases that affect normal brain function" 79 80 (10). Pathology associated with ADRD can begin decades before initial symptom presentation, 81 during the midlife period (11). Use of biomarkers such as those ascertained from cerebrospinal fluid and blood (e.g., amyloid beta, p-Tau) is particularly important to help identify protective 82 83 factors associated with lowering ADRD risk when symptoms have not yet manifested but 84 pathology may be present. While growing, research is limited on risk and protective factors in 85 relation to ADRD biomarkers with an eve toward cognitive reserve and resilience. In addition, research needs to expand to investigate neurobehavioral biomarkers strongly predictive of 86

5

87	ADRD but that are less invasive than the established biomarkers that require magnetic
88	resonance imaging (MRI), positron emission tomography (PET), cerebrospinal fluid (CSF), or
89	blood or skin biopsy collection (12), and that could be applied in clinical practice.
90	
91	The NIA-AA research ATN framework emphasizes the incorporation of biomarker measures of
92	amyloid, tau, and neurodegeneration/neuronal injury, providing an opportunity to classify
93	individuals across the AD spectrum (13). For instance, abnormal amyloid levels have been
94	consistently shown to predict subsequent cognitive decline as well as progression to mild
95	cognitive impairment and dementia (14-17). Risk of future decline among amyloid+ normal
96	controls is particularly high in those that also have abnormal tau (14, 18) or neurodegeneration
97	(19-21). Combining information across ATN dimensions allows identification of clinically normal
98	individuals who are in the earliest stages of the AD spectrum ("preclinical AD"). In addition, ATN
99	dimensions can be applied in differential diagnosis (13, 21-23), assessing target engagement
100	during clinical trials (24), and determine presence of other pathologies such as Lewy bodies (13,
101	25). Overall, the ATN framework provides a new perspective for studies of risk for and resilience
102	against ADRD. Recently, revisions have been proposed for the ATN framework to incorporate
103	other markers of neuronal injury, neurodegeneration, and coexisting pathologies (e.g., vascular
104	lesions, Lewy bodies).

105

The gaps in the literature on ADRD risk and protective factors, cognitive reserve, and resilience are particularly apparent for minoritized and disadvantaged populations (e.g., racial/ethnic minoritized and lower socioeconomic status (SES) groups) (26). It is critical for future work on brain health promotion and ADRD prevention to focus on protective factors for these populations, who also appear to be at higher risk of developing ADRD (6). For instance, Black and Hispanic individuals are 1.5 to 2 times more likely to develop ADRD than White individuals, and risk is highest amongst those with a combination of low education and low lifetime

6

113	occupational attainment (27). Factors that can be targeted via intervention to reduce ADRD risk
114	may differ between socially disadvantaged and advantaged individuals, and new cohorts are
115	needed with diverse populations including understudied immigrant populations.
116	
117	Studies on unique factors promoting cognitive reserve and resilience (beyond known risk
118	factors) that can be targeted via intervention to prevent ADRD remain limited. The Health Brain
119	Initiative (HBI) cohort was established by University of Miami's Comprehensive Center for Brain
120	Health (CCBH) to fill this gap and advance beyond the studies of healthy brain aging and ADRD
121	research to date. HBI will follow a racially/ethnically diverse cohort of ≥50-year-olds with normal
122	cognition, subjective cognitive complaints, mild cognitive impairment or very mild dementia from
123	the South Florida region. With ADRD prevention and brain health promotion as an overarching
124	goal, HBI will advance scientific knowledge on established and novel ADRD biomarkers,
125	examine additive effects of multiple factors (e.g., sociodemographics and lifestyle) on risk,
126	reserve, and resilience, and employ innovative and methodologically advanced methods to
127	characterize risk/resilience factors and disease progression.
128	
129	MATERIALS AND METHODS
130	
131	Study aims, design, and setting
132	
133	The HBI is a longitudinal, observational cohort study that will prospectively collect, analyze,
134	maintain, and store clinical, cognitive, behavioral, functional and neuroimaging data and
135	biospecimens from research participants, to allow a characterization of transitions in cognitive
136	status, studying risk and protective factors for cognitive and functional decline, and creation of a

repository of data for future research questions. The cohort will have representative sampling by

138 sex, race and ethnicity for normal cognition (NIA-AA Stage 1), subjective memory complaints

7

139 (Stage 2), MCI (Stage 3), or mild ADRD (Stage 4) according to the ATN framework (13). HBI's 140 specific aims are to: 1) Characterize novel approaches for detection of healthy brain aging and ADRD and 141 examine their relationship to ADRD biomarkers and ADRD-related outcomes (Aim 142 143 1); 2) Examine potential sociodemographic, biological, genetic, health and lifestyle additive 144 effects on the presence and accumulations of ADRD pathology detected via 145 biomarkers that may confer risk and resilience to cognitive decline (Aim 2); 146 147 3) Determine whether potentially modifiable risk factors across the life course buffer the 148 impact of brain pathology on cognitive decline and thus can serve as intervention targets (Aim 3); 149 4) Use machine learning and other advanced analytic techniques to explore trajectories 150 151 of disease progression by baseline health, lifestyle, and other risk factors (Aim 4); 152 and, 5) Conduct study aims with a racially/ethnically and socioeconomically diverse cohort 153 that will allow for examination of disparities in biomarkers, ADRD outcomes, and 154 155 risk/protective factors (Aim 5). 156 HBI will recruit a longitudinal cohort of 500 participants living in the racially/ethnically diverse 157 South Florida region, primarily Palm Beach and Broward counties. Multiple grant-funded studies 158 159 will use the standardized HBI protocol for data collection and thus contribute to the target 160 recruitment goals for HBI (e.g., NIH R01AG071514, R01AG071514S1, R01NS101483, 161 R01NS101483S1, RF1AG075901, and R56AG074889). 162

Recruitment will occur through a variety of sources, including advertisements, word-of-mouth,
 community lectures, health fairs, community events, educational conferences, physician

165	referrals, and working with community partners. HBI has an IRB-approved cross-sectional	
166	survey of risk and resilience factors that can be used to identify eligible individuals. Individuals	
167	who call the center will be provided with IRB-approved literature regarding the study objectives	
168	and inclusion/exclusion criteria. A full-time bilingual recruitment coordinator will work in	
169	conjunction with the research staff to organize and conduct recruitment activities.	
170		
171	Annual visits will be conducted at University of Miami's Comprehensive Center for Brain Health	
172	(CCBH) in Boca Raton, Florida. The visits will involve both the participant and their study	
173	partner, who is typically a spouse or adult child who provides independent, collateral informatior	
174	on the participant. Our prior research has demonstrated the importance of the caregiver-patient	
175	dyad to longitudinal outcomes (28-31).	
176		
177	Inclusion and exclusion criteria	
178		
179	The target sample of 500 individuals to be followed longitudinally will include those who:	
180	• Are ≥50 years old,	
181	Have no cognitive impairment, subjective cognitive impairment (SCI), mild cognitive	
182	impairment (MCI), or any cause of dementia or neurodegenerative disease at the mild	
183	stage (Clinical Dementia Rating (CDR®)≤1),	
184	• Have a study partner; and,	
185	Are medically eligible to undergo MRI.	
186		
187	Individuals will be excluded if they:	
188	Do not consent for data/specimen storage,	

9

189	Have already been diagnosed with moderate or severe ADRD (Clinical Dementia
190	Rating≥2 (32)),
191	Cannot contribute clinical, cognitive, behavioral, or functional data; or,
192	Have significant medical illness that could affect participation in imaging or obfuscate
193	relevant cognitive outcomes (e.g., metastatic cancer, primary Axis I disorder such as
194	schizophrenia, Axis II personality disorder, unstable diabetes or hypertension, or
195	substance abuse within the past 5 years).
196	
197	Procedures
198	
199	Baseline visit. Participants and their study partners will be consented at the baseline visit, and
200	then reconsented at annual follow-ups if needed. Following informed consent, the participants
201	will complete a battery of questionnaires collecting information such as demographics, medical
202	history to identify possible risk factors for memory problems (e.g., high blood pressure, strokes,
203	heart disease, diabetes, other potentially relevant comorbidities), lifestyle activities, and
204	resilience and vulnerability factors (Tables 1 and 2).
205	
206	Once the battery of questionnaires is completed and reviewed by the study team for

207 completeness, the baseline visit is scheduled. The visit will include blood sample collection,

208 detailed neuropsychological, physical function, neurological, and psychosocial assessments,

and participants receive an actigraphy and peripheral arterial tone device (i.e., Watch PAT) for

overnight sleep monitoring and have their MRI scheduled (Table 3). The full baseline visit is

211 expected to take two half days to complete. Participants recruited for certain grant-funded

212 projects that include the HBI assessment also will be scheduled to obtain an amyloid PET using

213 18F-Fluorbetaben.

10

215 The research visit concludes with a feedback session during which a research clinician (e.g., 216 physician, nurse practitioner) meets with the participant and study partner (optional) to go over results of the neurological examination, physical performance, neurobehavioral status, and 217 cognitive evaluation. This meeting also will provide health recommendations, education, 218 219 resources and referrals based on the findings. This feedback can be shared with family and/or a 220 doctor at the participant's request. Once reviewed, participants will receive a summary of clinical laboratory results from a CLIA-approved lab. If any abnormalities are detected, the 221 222 participant will be informed of results and encouraged to speak with their primary care provider 223 for further evaluation. Results of genetic testing will not be shared with either the participant or their physicians as described in the consent form. 224 225 226 In-person follow-up visits. Annual follow-up visits will collect almost identical data as the 227 baseline visit, and will include the neuropsychological battery, neurological evaluation, physical performance testing, and blood work, so that we can monitor annual changes in cognitive and 228 physical status and biomarkers for ADRD. MRI are conducted every 2 years following the 229 baseline visit, unless a clinically relevant event (e.g., conversion to dementia, stroke) occurs 230 231 whereby they may be asked to undergo an MRI earlier. 232 Telephone follow-ups. At 3 and 6 months after the baseline visit and then at 6 months after the 233 234 follow-up visits, each participant will be contacted by phone to update contact information, 235 health history and medications, collect data on their cognition and everyday functioning, assess adherence with recommendations and referrals provided at the feedback session, and to 236 237 support study retention.

238

239

11

241 Physical and neurological examinations

242

243	Each participant will provide information about their current and past health history (e.g.,
244	medical, social, physical, environmental) through a 20-page self-administered questionnaire
245	prior to the core visit. To confirm or rule out various types of neurodegenerative diseases
246	(ADRD) a series of tests and examinations will be conducted during the study visit. The results
247	of these procedures will be documented and used to relate objective and subjective findings,
248	measures, and complaints for an accurate research diagnosis for each participant. Each study
249	partner will complete an 11-page survey.
250	
251	Advanced practice nurses and neurologists will complete a comprehensive physical and
252	neurological examination of each participant (33, 34). This examination will include
253	assessments of vital signs in a sitting and standing position, mental status, cranial nerve,
254	reflexes, sensation, balance, coordination, and motor skills and includes the Unified Parkison's
255	Disease Rating Scale – Part III Motor Examination (35), modified Hoehn and Yahr staging (36),
256	Lewy Body Composite Risk Score (37), modified Hachinski Ischemic Scale (38), and modified
257	CAIDE scale (39).
258	
259	Overnight Sleep Study. A disposable FDA-approved at home diagnostic test for sleep apnea will

be given to each participant to wear overnight following the core visit procedures (40). This actigraphy and peripheral arterial tone device is placed on the wrist of the non-dominant hand, a probe is placed on the index finger of the non-dominant hand, and a sensor is placed on their chest just below the sternal notch. A smartphone is used to accompany the device using an app to start and end the test.

12

266	Audiometry. Headphones and a tablet computer with auditory testing software will be given to
267	each participant (41). The hearing test will be conducted in a private space free of distractions
268	for a duration of about ten minutes. Participants will be able to use the tablet independently after
269	listening to the instructions provided on the tablet.
270	
271	Spirometry. This test requires the participant to take a deep breath and then expel all the air in
272	their lungs into a filtered mouthpiece that is connected to a spirometry device (42). This
273	machine can measure peak expiratory flow (PEF), PEF%, FEV1 (forced expiratory volume),
274	FEV1%, FVC (forced vital capacity), and FEV1/FVC.
275	
276	Ankle Brachial Index. Cuffs are wrapped around the arm (brachial) and ankle (dorsalis pedis
277	and posterior tibial) arterial sites bilaterally and a handheld doppler ultrasound device is used to
278	measure systolic blood pressure while the participant is in a supine position at rest for 5 to 10
279	minutes (43). This test will be used to assess peripheral artery disease.
280	
281	Color Blindness Test. The Farnsworth D-15 Dichotomous Color Blindness Test will be
282	administered digitally on a computer or laptop. Participants will be asked to arrange 15 color
283	squares in order by choosing the most similar color and dragging the color squares into the
284	upper boxes (44, 45). A pilot square is set as the first box.
285	
286	Cognitive assessments
287	A comprehensive battery of both traditional (pencil and paper) and computerized tests will be
288	employed to longitudinally assess aspects of cognition and mood. The battery will be conducted
289	at baseline and then repeated at each subsequent annual follow-up. Specific tests and their
290	associated details are provided below.

13

292 The Clinical Dementia Rating scale (CDR; 46) is a semi-structured interview, involving both the 293 participant and a study partner, gauges cognitive and functional performance across six domains: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and 294 295 Hobbies, and Personal Care. The CDR has good reliability and validity and detects subtle 296 cognitive changes and everyday functioning. Each domain receives a score between 0 (no 297 impairment) and 3 (severe impairment). An aggregate global score is then derived, indicating overall dementia severity (i.e., 0 =normal, 0.5 = MCI, 1,2,3= mild, moderate, or severe 298 299 dementia, respectively). The sum of boxes score (CDR-SB) is calculated by summing domain 300 scores with possible scores ranging from 0-18, with higher scores indicating greater impairment. 301 The Global Deterioration Scale (GDS; (47)) is a rating scale of cognitive status with a range of 302 303 scores from 1-6. The GDS has advantages over the CDR by providing separate ratings for 304 cognitively normal individuals with and without cognitive complaints. GDS 1 signifies cognitively normal individuals without any subjective complaints; GDS 2 signifies cognitively normal 305 306 individuals with subjective complaints; GDS 3 signifies the earliest objective cognitive deficits equivalent to MCI; and GDS 4 signifies clear cut cognitive and functional deficits equivalent to 307 308 mild dementia. GDS 5-7 designate moderate through severe stages of dementia. 309 The Hopkins Verbal Learning Test-Revised (HVLT; 48) is a neuropsychological assessment tool 310 used to assess verbal learning and memory. Participants are instructed to recall a list of 12 311 312 noun-words over three trials. Total words correctly recalled across three trials (max 36). The number of correctly recalled words following a 20-25-minute delay (range 0-12) is used as a 313 measure of free recall. The number of correctly identified words from the yes/no recognition task 314 315 (range 0-12) is used as a measure of cue recognition memory.

14

317 The Montreal Cognitive Assessment (MoCA (49)) is a widely utilized cognitive screening instrument designed to identify mild cognitive impairment. Cognitive domains assessed include 318 Visuospatial/executive functions, language, memory attention, delayed recall and orientation. 319 320 The MoCA has a total possible score of 30, with a score of 26 or above considered within a 321 normal range, while scores between 18 and 25 are suggestive of MCI, and below 18 is 322 suggestive of dementia. 323 324 *Number span - Forwards* (50) is used as a measure of simple auditory attention. Participants 325 are presented with an increasing sequence of numbers over several trials and are required to repeat them back. The longest sequence correctly repeated is used as the measure of 326 attentional capacity with a score range of 0-9. 327 328 329 Number span – Backwards is used as a measure of auditory working memory. Participants are asked to repeat number sequences in reverse order. The longest backward-repeated sequence 330 is used as the measure of working memory with scores ranging from 0-8. For forwards and 331 backwards span, higher scores denote better performance. 332 333 Noise Pareidolia Task - Short Form (51) is a neuropsychological assessment designed to 334 evaluate an individual's propensity to perceive faces within ambiguous black and white patterns, 335 336 offering insights into the phenomena of pareidolia and potential neurological or psychiatric 337 implications of this perceptual bias. Following a practice trail, participants view multiple patterned items. For each, they respond to, "Do you see a face?", marking the perceived face's 338

- location if positive. Scoring categories include Correct Face Responses with a range of 0-7,
- indicating accurate identification of actual faces; Correct Noise Responses ranging from 0-13,
- 341 denoting accurate rejection of patterns without faces; a Total Correct score combining the two
- 342 previous scores with a range of 0-20; and Noise (Pareidolia) Responses, capturing incorrect

15

343	identifications of faces in noise-only patter	rns, with a possible range of 0-13. A h	nigh score
-----	---	---	------------

- 344 indicates better perceptual discrimination, while frequent false positives (seeing faces where
- none exist) might point to a heightened propensity for pareidolia.
- 346

347 *The Animal Naming task* (52): This is used is a widely used measure to assess semantic

fluency. Participants are asked to name as many different animals as quickly as possible within

349 60 seconds. The total score represents the number of distinct animals named within the allowed

time, and higher scores indicate better semantic fluency and retrieval ability.

351

The 32-item Multilingual Naming Test (MINT; 53) is a standardized instrument designed to 352 quantify confrontation naming ability. Participants are presented with a set of 32 pictorial stimuli, 353 354 each representing distinct objects, and are tasked to elicit the corresponding lexical 355 representation. The MINT aims to assess lexical retrieval and object recognition capacities, integral elements of linguistic processing. Furthermore, the test's construct is curated to mitigate 356 357 biases across diverse linguistic and cultural demographics. Scoring is systematic: each correctly identified stimulus contributes one point, culminating in a maximum possible score of 32, which 358 359 is indicative of optimal linguistic processing capability.

360

The Trail Making Test (TMT; 54) is a widely recognized neuropsychological assessment used to 361 examine cognitive flexibility, visual search, motor speed, and executive functioning. Comprising 362 363 two main components, Trails A and B, the test evaluates both simple psychomotor speed and more complex task-switching abilities. Trails A requires participants to connect numbered circles 364 365 (1-25) in ascending order as quickly as possible. The time taken in seconds to complete is used 366 as a measure of processing speed. The max time to complete the test is 180 seconds. Longer 367 completion times suggest poorer performances. Trails B is a widely used measure of task switching, cognitive flexibility, and executive functioning. In this task, participants are asked to 368

16

connect numbers and letters in ascending order (e.g., 1-A-2-B-3-C, etc.). The completion time in
seconds is used as the outcome measure. The max time to complete the test is 300 seconds.
Longer completion times suggest poorer performances.

372

Number symbol coding (55): The NSCT is a brief measure of processing speed, attention, and
working memory that can be completed by individuals into the moderate-to-severe stages of
dementia. In the task, participants are typically required to match numbers with specific symbols
within 90 seconds. Its streamlined nature allows for efficient administration. A score of 36 or
below indicates cognitive impairment with possible scores ranging from 0-70.

378

The AD8 (56) is an informant-based interview designed to assess for signs and symptoms of 379 380 dementia. The instrument is grounded in the principle that study partners (often close family 381 members or friends) can provide crucial insights into an individual's cognitive and functional changes over time. The AD8 evaluates various domains, including memory, orientation, 382 executive function, and interest in activities, through a series of eight questions. The study 383 partner is asked to compare the individual's current cognitive and functional performance with 384 385 their performance in the past. Responses indicating change consistent with cognitive decline are scored, with a higher score suggesting a greater likelihood of dementia. A score of 2 or 386 more on the AD8 indicates that further dementia evaluation is warranted. 387

388

The Clock Drawing Test (CDT (57)) is an established neuropsychological screening tool used to assess visuospatial abilities, executive functioning, and attention. This test requires participants to draw the face of a clock on a blank sheet of paper and then set the hands to a specified time, "10 minutes past 11." Scoring the CDT can range from a basic dichotomous "normal/abnormal" rating system that consider various aspects of the drawing, such as the presence and correct

17

sequencing of numbers, correct placement and proportion of the clock hands, and overallspatial organization.

396

397 The Craft Story (58) is a measure of verbal episodic memory. It consists of a short narrative that 398 is read aloud to participants, who are then asked to recall as much information from the story as 399 possible immediately after hearing it (Immediate Recall) and again after a specified delay 400 (Delayed Recall), approximately 20 to 30 minutes later. Scoring is typically based on the 401 number of thematic units (score range: 0-25) or specific details accurately recalled verbatim 402 (score range: 0-44). Higher scores indicate better verbal learning and memory.

403

The Benson Complex Figure Test (BCFT; 59) is used to assess visuoconstructive skills, visual 404 405 memory, and recognition. Participants begin by drawing a copy of a complex geometric figure 406 ("copy" trial). After a delay of approximately 30 minutes, they are asked to redraw the figure from memory ("delayed recall" trial). Lastly, in the "recognition" trial, participants are asked if 407 they recognize the figure from an array of figures with a yes-no response. Scoring is based on 408 the accuracy and organization of drawings, types of errors in reproduction, and the accuracy of 409 410 recognition. The BCFT is particularly useful for identifying cognitive deficits, especially those associated with right hemisphere dysfunctions. For the copy and delayed recall trial, a possible 411 score of 0-17 can be obtained, with higher scores indicating better performances. 412

413

Cognivue® (60) is a computerized comprehensive cognitive assessment tool that evaluates a range of specific cognitive domains, including motor speed, visuospatial abilities, verbal and visual episodic memory, attention, executive functioning, and reaction time. Using adaptive psychophysics, it adjusts task difficulty in real-time based on participant responses. The assessment, which takes about 10 minutes, provides a numerical score categorizing performance as "normal," "mild impairment," or "moderate impairment." Cognivue® is Food and

18

Drug Administration (FDA)-cleared for use as an adjunctive tool to aid in assessing cognitive
impairment in participants aged 55-95 years.
Anxiety and depressive symptoms *The Hospital Anxiety and Depression Scale* (HADS; 61) is a validated instrument for screening
symptoms of anxiety and depression in medically ill populations, specifically within nonpsychiatric hospital contexts. The HADS encompasses 14 items, divided into two subscales: the

427 Anxiety subscale (HADS-A) and the Depression subscale (HADS-D). Each item is appraised on

428 a 4-point Likert scale, resulting in individual subscale scores that can range from 0 to 21.

Interpretation of scores on both subscales is as follows: 0-7: Normal; 8-10: Borderline; 11-21:

430 Abnormal. The HADS is recognized for its strong psychometric properties and has been

431 employed extensively across various clinical cohorts.

432

Depression, Anxiety, and Apathy Assessment (DA³) is a 21-item questionnaire assessing how
participants have felt and their experiences during the previous 2 weeks. Questions such as "I
feel tense and unable to relax", "I am able to get things started and completed", and "I have
trouble focusing my thoughts" are answered on a 4-point scale (0=rarely, 1=sometimes,
2=often, or 3=always). Items are summed to provide a depression score (DA3-D, range: 0-7),
an anxiety score (DA3-An, range: 0-7), and an apathy score (DA3-Ap, range: 0-7).

439

440 Physical function assessment

441

442 At baseline and each annual follow-up visit, HBI participants will undergo extensive

443 performance-based physical functional assessments including body composition, muscle

strength, balance, physical performance, and computerized gait analysis. Participants will be

asked to come in wearing comfortable clothing and shoes and will start the physical functional

19

446	assessment with a series of body measurements (i.e., height, hip-, waist-, and neck-girth) taken
447	with wall-mounted or handheld tape measures. Weight will be measured with InBody, a
448	bioimpedance-based body composition analyzer, which provides estimates of weight, BMI,
449	skeletal muscle mass, fat mass including visceral fat, intracellular and extracellular water
450	content, basal metabolic rate, and other body composition indicators (InBody USA; 770 series).
451	
452	Muscle strength will be measured in the upper extremities with a Smedley Digital Hand
453	Dynamometer (Baseline® Evaluation Instruments, Version 12-0286) for a total of three trials in
454	each hand, with the average across the three trials used in data analysis. Sarcopenia status is
455	reported using the Short Portable Sarcopenia Measure (SPSM) (62). The SPSM score ranges
456	from 0-18, with lower scores indicating greater likelihood of sarcopenia.
457	
458	The mini-Physical Performance Task (mPPT) consists of 4 tasks: (1) Bending Over Test for
459	which participants will be asked to bend over without bending their knees to pick up a binder clip
460	placed about 1 foot from their foot on the dominant side; (2) a 50-foot timed walk task, (3) the 5
461	Times Sit to Stand Test (5XSST) using a sturdy 4-leg non-rolling chair with hand support, with
462	the participants asked to rise and sit down in the chair as fast as they can for a total of five times
463	without using the armrests; and (4) the Progressive Romberg Balance Test (PRBT) for which
464	participants are timed as they complete 10-second side-by-side, semi-tandem, and tandem
465	balance tasks (63). The mPPT score ranges from 0-16 with higher scores indicating greater
466	physical functionality.
467	
468	Participants will undergo a complex gait and balance evaluation on an electronic pressure-
469	based walkway (Zeno Walkway TM) and data processed using the ProtoKinetics Movement

470 Analysis Software (ProtoKinetics, Version 6.00C1). The Zeno Walkway provides a wealth of

temporal and spatial measures of gait associated with fall risk including velocity, cycle time, %

20

stance, step length, stride width, % swing, % single support, and other kinetic and kinematic gait
parameters. The HBI protocol requires completion of a series of walking tests performed on the
Zeno Walkway in the following sequence: (1) Single-task (walking at normal pace + no
concurrent cognitive task); (2) Dual-task (walking + reciting the alphabet); (3) Dual-task (+ serial
subtraction); and (4) Dual-task (+ texting) with parameter estimates derived for each of the four
walks.

478

Balance and risk of fall also will be assessed with 1) Limits of Stability (LOS) and 2) Four 479 480 Square Step Test (FSST). LOS measures how much an individual can lean in four directions: the mediolateral (left/right) and anteroposterior (forward/backward) directions/axes while 481 standing with their feet shoulder width apart. LOS starts with the participant standing for 30 482 483 seconds in quiet standing (QST) with their arms by their side with eyes open. Participants are 484 then asked to lean forward as far as they can without taking a recovery step or falling, return to center, then lean left, return to center, lean backward, return to center, and finally lean right and 485 return to center. While no specific amount of time holding the lean is required, the rater is 486 assessing whether the lean is held for a minimum of 2 seconds. One trial is conducted for the 487 488 LOS and QST tests, with one retake allowed. FSST is a dynamic test of balance and coordination which involves stepping as fast as possible in each of 4 squares with both feet in a 489 490 predetermined sequence (64). Participants are allowed to practice one time before testing commences with one retake permitted in case of tripping or incorrect step sequence. Two trials 491 492 are completed for FSST, with the better time (in seconds) being recorded as the score. Both LOS and FSST are conducted with the Zeno Walkway inertial sensor waist belt to capture trunk 493 excursion. 494

495

Timed up and Go (TUG) is a timed assessment that requires a person to stand (handsfree) from
a chair walk 3 meters and return to sitting (handsfree) (65, 66). It is considered a gold standard

indicating falls risk in older adults. Cognitive TUG i(TUG-Cog) is TUG with the addition of a
cognitive task such as serial subtraction (e.g., subtract 87 by 3).
Kinetisense is a markerless motion capture analysis system that uses infrared cameras to
identify the kinematics of moving joints (67, 68). It provides real-time biofeedback on the
performance of balance, gait, and functional activities in coronal, sagittal, and transverse
planes. Kinetisense produces video playback and generated reports that include a risk of fall
gait assessment that is calculated based on normative gait parameters and when combined with
other gold standard physical performance assessments such as the TUG and STSX5, provides
ergonomic feedback of a person's overall function and balance.
Three global measures of frailty are determined at each visit. The Rockwood Frailty Index (69),
the Fried Frailty Phenotype (70), and the CHSA Clinical Frailty Scale (71). Higher scores on the
frailty scales are suggestive of greater likelihood of being frail.
Blood- and saliva-based biomarkers and genetics
A custom panel of tests (i.e., Healthy Brain Initiative (HBI) Profile) will be conducted. At the start
of the core visit, blood will be drawn from each participant by venipuncture by trained
phlebotomists. Participants also provide saliva samples for DNA extraction and APOE e4
carrier status. Saliva will be obtained through self-collection kits. The collected specimens will
be processed and used to evaluate plasma biomarkers, genetic data, and metabolic panels, and
then stored in a biorepository for future research as plasma, whole blood, and DNA. Measures
collected include a comprehensive metabolic panel, cortisol, cystatin C, hemoglobin A1C,

- 522 insulin resistance, homocysteine, high-sensitivity C-reactive protein (hs-CRP), a complete lipid
- 523 panel with particles, thyroid stimulating hormone, vitamin B12, folate, vitamin D, apolipoprotein

22

E (APOE) e4 status, and multiple plasma ADRD biomarkers (e.g., Ab42, Ab40, p-tau). Blood
specimens will be processed in HBI's lab for shipment to C2N laboratories for analysis. C2N
employs mass spectrometry to calculate multiple plasma AD biomarker values including
Ab42/40, p-tau181, p-tau217, and p-tau/np-tau. Additionally, the HBI lab conducts in-house
measurements of biomarkers such as neurofilament light (NFL), glial fibrillary acidic protein
(GFAP), and TAR DNA-binding protein 43 (TDP-43) on Quanterix SIMOA™ platforms for each
participant.

531

532 Machine-based assessments

533

Optical coherences tomography (OCT), an imaging technique using near-infrared light to 534 capture detailed images of the cornea, lens, retinal tissue, anterior chamber, and retinal 535 536 vasculature, is an emerging technology in ADRD research. The retina is embryologically derived from the same tissue as the cerebral cortex, and pathological changes in cortical gray matter 537 appear in the retina as well, including deposits of amyloid- β revealed using targeted tracers (72, 538 73). Retinal measurements include the central subfield thickness, the volume and thickness of 539 540 the macula, the thickness of the retinal nerve fiber layer, internal plexiform layer thickness, and the ganglion cell layer thickness. The minimum thickness of both the ganglion cell layer and the 541 internal plexiform layer is also collected and is strongly associated with various cognitive 542 543 domains and the CDR sum of boxes along with the combined ganglion cell layer and internal 544 plexiform layer thicknesses (74). By collecting these data in HBI, we aim to explore the use of these markers in determining current impairment through non-invasive imaging procedures as 545 well as identifying risk of future impairment based on the health of retinal tissue (75-77). 546

547

548 *Neurobehavioral markers*, including gaze behavior and speech behavior, have been shown to 549 identify longitudinal changes in prodromal dementia, with some research showing an ability to

550	identify preclinical impairment through the examination of connected speech production (78-80).
551	Gaze behavior assessed through eye movements during cognitive assessment tasks further
552	capture differences between not only cognitively normal participants and impaired participants
553	through the examination of exploratory behavior and novelty preference, but differentiation of
554	likely cause of impairment including separating DLB and PD from AD using saccadic behavior
555	(75, 81, 82). Eye movements are collected using Tobii Pro eye trackers, including the Tobii
556	Dynavox and the Tobii Pro Spectrum, and audio metrics including speech are collected using
557	hypercardioid directional microphones for reducing extraneous background noise. These
558	markers are collected while picture description, narrative recall, and visual search tasks are
559	administered to participants using custom-designed experimental software written in Python and
560	C++.
561	
562	
563	
564	Neuroimaging procedures and measures
565	
566	MRI. All participants will have brain MRI scans using a GE 3 Tesla 750W scanner at baseline and
567	every 2 years. We will collect high-resolution 3D sagittal Magnetization-Prepared Rapid Gradient-
568	Echo (MPRAGE) images with axial and coronal reconstructions to quantitate brain atrophy. We will
569	use axial 3DT2 FLAIR and 2D T2* brain images to quantify white matter hyperintensities (WMH),
570	infarcts, microhemorrhages and superficial siderosis. We will collect diffusion-weighted images
571	(diffusion tensor imaging) to measure mean diffusivity and fractional anisotropy to estimate
572	microstructural integrity and white matter tractography. Last, we will collect resting BOLD
573	sequences for functional MRI analyses. The total imaging time sequences is estimated to be 45
574	minutes. The MRI sequences selected for this project are modified from the ADNI-3 canonical

24

576

577 In addition to visual reads for MRI scans, post-processing of all MRI images will be performed according to ADNI procedures, including correction for geometric distortion of gradient nonlinearity, 578 579 field inhomogeneity correction, histogram-peak sharpening, and correction for site-specific scanner 580 features/field strength. Cortical, subcortical, ventricular, and white matter hyperintensity volumes 581 are analyzed using Combinatics® cNeuro Suite, an FDA-cleared quantitative pipeline. Automated brain imaging quantification using artificial intelligence (AI) technology offers many opportunities 582 583 to reduce the time needed for imaging analysis and increase the accuracy, precision, 584 consistency, robustness, and, as a consequence, the research quality of the data. Combinostics cMRI suite is comparable to manual segmentation with Pearson coefficients ranging from 0.84 585 to 0.99. The cMRI suite contains important dementia biomarkers including hippocampal, inferior 586 587 lateral ventricle, cerebral white and gray matter, cerebral cortex, and medial temporal lobe 588 volumes, and a global cortical atrophy index with an 85% sensitivity and 86% specificity. White 589 matter integrity and myeline measures will be conducted using Synthetic MRI®, an FDA-cleared 590 Al pipeline providing quantitative measurements of intracranial, brain parenchyma, myelin, cerebrospinal fluid volumes and brain parenchymal and myelin correlated fractions. 591 592 PET. Participants who consent will have baseline amyloid PET scans with ligands from Life 593 Molecular Imaging. Non-contrast enhanced computerized tomography (CT) is used for 594 595 attenuation correction of the PET images and for morphological localization through image 596 fusion between PET and CT. PET scans will be processed using the reconstruction algorithm provided to include attenuation correction with an image matrix size of 128 x 128, and a 597 598 transaxial pixel size of 2-3 mm. Participants will undergo an amyloid PET scan using Neuraceg™ (F18 Florbetaben injection), an amyloid PET ligand that received FDA approval in March 2014. 599 600 8.1 mCi +/- 20% of Neuraceg will be administered as a single bolus intravenous injection at a 601 rate of 6 seconds/mL in a total volume of up to 10 mL. Approximately 10 minutes prior to the

602	initiation of the PET scan, the participant will be positioned in the PET scanner. The head will be
603	positioned such that the entire brain including the cerebellum will be in the field of view (FOV).
604	An attenuation correction image will be acquired following standard procedures. PET imaging
605	will commence 90 min post injection for a total of 20 min (4 x 5 min frames). SUVR images will
606	be created using 90 min after injection and used for qualitative reads and to extract global
607	values. The Combinostics cPET $\ensuremath{\mathbb{R}}$ suite provides a segmental analysis of FDG and amyloid PET
608	with regional and global SUVRs and for amyloid PET calculates the Centiloid Level.
609	
610	Data and biospecimen repository
611	
612	The data repository will consist of clinical, cognitive, behavioral, and functional data as well as
613	summary data from plasma, DNA, and imaging biomarker studies that will be kept in both paper
614	and electronic form and kept in locked cabinets within locked offices and compiled in a REDCap
615	electronic database accessible via protected passwords. The database will contain all data
616	derived from interviews of participants and study partners, neuropsychological and physical
617	performance assessments, medical exams, as well as summaries of blood and imaging data.
618	Physical records of neuroimaging studies will be placed in participant files kept in locked file
619	cabinets and summary results will be kept in a separate protected electronic file.
620	
621	Blood specimens are processed in the lab for shipping to commercial laboratories for analysis
622	and for storage in -80°C freezers located in the lab (with generator backup). Buffy coat will be
623	extracted from blood for future DNA studies. All specimens collected will be stored in the CCBH
624	laboratory refrigerator and freezers, which are only accessible by CCBH laboratory personnel.
625	The specimens will be kept indefinitely.
626	

26

627 Biological samples will be sent to the National Centralized Repository for Alzheimer's Disease 628 and Related Dementias (NCRAD) for sharing with other investigators. NCRAD is a national resource supported by the National Institute on Aging (NIA) that prepares and stores biological 629 specimens from all over the world and makes them available to approved scientists who would 630 631 not otherwise be able to access this material. Biological samples will be de-identified and maintained in the CCBH laboratory indefinitely. These biological samples allow for studies of the 632 633 causes of many diseases, including ADRD. 634 635 **Primary HBI outcomes** 636 The primary outcome of HBI is to improve our understanding of what healthy brain aging is, and 637 638 how to best detect the earliest signs of MCI/ADRD in diverse populations. This is accomplished 639 via deep phenotyping, biomarker collection, and genetic (including epigenetic) markers. This work has allowed us to develop the brain health platform (described below) and leverage the 640 ATN framework to begin to take a precision medicine approach to brain health and ADRD 641 detection, and eventually treatment and prevention. 642 643

Brain health platform. The Brain Health Platform (84) guantifies brain health and identifies 644 ADRD risk factors based on 3 measures collected that will be collected at HBI: Resilience Index 645 (RI) (85), the Vulnerability Index (VI) (86); and the Number-Symbol Coding Task (NSCT) (55). 646 647 VI and RI scores (range: 2-20 and 1-378, respectively) are calculated from demographics, lifestyle questionnaires, physical assessments, medical history, and neuropsychological 648 examination. Details of the Brain Health Platform including the VI and RI are published 649 650 elsewhere (85, 86). By combining measures of performance, resilience, and vulnerability, it 651 provides an overall snapshot of the participant's brain health at a given visit. Instead of a

27

summary score, the platform indicates whether participants are at low, intermediate, or high riskof being cognitively impaired.

654

ATN Staging. Once a sufficient number of individuals have completed MRI, amyloid and tau 655 656 PET, and plasma ADRD biomarkers, we will use the distribution of values within the normal control group to z-score individual participants and provide categorization consistent with the 657 ATN (amyloid tau neurodegeneration) research framework (13). Given the bimodal and global 658 659 distribution of amyloid PET data, Gaussian mixture modeling will be used to identify A- and A+ 660 distributions. Categorization of Tau PET into Braak III and above will be used to classify individuals as T- or T+ and hippocampus volume will be used to classify individuals as N- or N+. 661 This will be matched to plasma Ab40, Ab42 (A- and A+), Tau and p-tau (T- or T+), and NFL (N-662 or N+). Further, we can consider other pathologies in the form of MRI white matter 663 664 hyperintensities for vascular disease (V- or V+), plasma alpha synuclein and phospho-synuclein for Lewy body pathology (S- or S+), and plasma TDP-43 (P- or P+). This will permit testing of 665 the ATN framework in a systematic fashion in a deeply phenotyped cohort. 666 *Clinical diagnoses.* A clinical diagnosis of the participant's cognitive status (normal cognition, 667 668 MCI, or dementia) and their ADRD etiological diagnosis (e.g., Alzheimer's disease or Lewy body disease) is determined via consensus conference of the HBI clinicians. To make the diagnosis, 669 clinicians review the neuropsychological test findings and supporting clinical data independent 670 of the biomarker data and follow consensus criteria guidelines (2, 3, 87-90). 671 672 Intermediary/secondary outcomes 673

674

Beyond the ATN framework, Brain Health Platform, and clinical diagnoses, which capture

676 presence of disease or risk of developing disease, continuous measures of the ADRD

28

biomarkers and functional and cognitive test scores (e.g., longitudinal change in plasma
Ab42/40, frailty scores, or executive function over time) will serve as intermediary outcomes.

679

680 Novel approaches in the HBI

681

Precision medicine. Precision medicine is a model that permits the separation of patients into 682 different groups to better inform and tailor medical decisions, practice, and treatment to defined 683 684 subgroups based on their (a) predicted responses and/or (b) risk of disease (91-93). Precision 685 medicine approaches can help shift medical practice from reaction to prevention, predict susceptibility, improve early detection, and eliminate trial and error treatment thereby avoiding 686 or limited negative side effects and maximizing efficacy (94). Commonly used in oncology, 687 688 precision medicine has expanded to other fields. Precision medicine approaches are typically 689 genome-based using tissue markers acquired via biopsy or genetic markers in blood. In the case of ADRD, biopsy is not a viable path and genetic causes of disease are limited. Instead, 690 691 HBI has focused on deep phenotyping individuals to examine small deviations from normal or expected structure, function, and behavior. Using this detailed and comprehensive picture, HBI 692 693 will better characterize factors that make individuals (a) more likely to develop disease (i.e., vulnerability) or less likely to develop disease (i.e., resilience) (95, 96). 694

695

Machine learning. Given the vast quantities of data generated through the HBI, machine
learning techniques become viable and, in some cases, preferable compared to more traditional
statistical techniques of data analysis. Model generation using supervised learning techniques,
including both classification and regression, enables hypothesis testing of diagnostic and
screening techniques, leading to developments such as multi-stage screening systems and the
identification of markers associated with early-stage and prodromal cognitive impairment

29

including groups of cognitive assessments as well as markers of vulnerability and brain health(84, 86, 97, 98).

704

705 Geospatial data and the exposome. HBI will collect residential addresses and self-reported 706 environmental exposures and behaviors from various time points during the participant's life 707 course from childhood to later life. These data will address HBI's specific aim to determine how sociodemographic and lifestyle factors contribute to risk for and resilience against ADRD. HBI's 708 709 life course measures will target key domains of the exposome, which has been defined as the 710 "exposures of an individual in a lifetime and how those exposures relate to health" and 711 encompasses all non-genetic determinants of health (99). Domains to be captured in HBI center on "general external" exposome measures of social context (e.g., participant's and 712 713 neighborhood SES) and the neighborhood built environment (e.g., greenspaces, sidewalk 714 availability), as well as "specific external" exposome measures encompassing lifestyle behaviors (e.g., diet, exercise, medication use). The measures will either be collected via self-report by the 715 716 participant or study partner or will be derived by geocoding addresses to identify the latitude-717 longitude and/or Census tract location and linking to built and social environment data from 718 sources such as the US Census, the Neighborhood Atlas (100), and satellite imagery from the 719 US Geological Survey (101).

720

Epigenetics. DNA methylation (DNAm) is an epigenetic modification where a methyl group attaches to DNA's cytosine nucleotides, often at CpG sites (102). This process can vary with cell type, developmental stage, and environmental conditions (103, 104) has emerged as a pivotal biomarker of biological aging, with its profiles often referred to as "epigenetic clocks" (105). These clocks hint at disparities between chronological and biological age, with greater than expected biological ages associated with increased risk for neurodegenerative disease and earlier mortality (105-107). Specific lifestyle risks, such as hypertension (108, 109) and obesity

30

728 (110), correlate with distinct DNAm changes in genes governing vascular function,

neuroinflammation, and cognition (111, 112). In essence, DNAm may offer a potential pathway
 through which cognitive health disparities may arise.

731

732 Our objective for collecting DNAm data will be to improve and refine current epigenetic age 733 clocks to brain aging while also seeking an in-depth investigation of associations between DNAm profiles and various lifestyle factors. This endeavor is geared towards a comprehensive 734 735 understanding of the relationship between DNAm alterations and brain health, with a focus on 736 the molecular determinants underpinning aging processes. Whole blood samples (10 mL) from HBI participants will be used for DNAm data extraction. DNAm extraction will be performed 737 using the Infinium Methylation EPIC BeadChip 850k platform the Center for Genome 738 739 Technology at John P. Hussman Institute for Human Genomics, University of Miami Miller 740 School of Medicine. Using these data, our objective is to construct refined epigenetic clocks that 741 provide enhanced precision in estimating biological age and its divergence from chronological 742 age.

743

744 Transdisciplinary and multidisciplinary study team approach. The HBI team was purposefully constructed to be multidisciplinary and transdisciplinary, including individuals from varied 745 disciplines who continuously collaborate, infusing conceptual knowledge and methodologies 746 747 unique to each discipline to inform not only the cohort study protocol but also in the methods, 748 analyses, and means of reporting results when addressing the HBI's specific aims. The multidisciplinary team includes physicians, nurse practitioners, nurses, social workers, physical 749 therapists, gerontologists, cognitive neuroscientists, biostatisticians, bioinformatic analysts, 750 751 molecular scientists, data scientists, geographic information system specialists, and an urban planner. The HBI team structure and personnel expertise/skills will be modified as needed to 752 753 increase efficiency and accommodate new research initiatives.

754 Data management plans and data security

755

Data management is handled by the CCBH Data Core, which includes a Data Manager, Data 756 757 Scientists, and trained data entry personnel. CCBH uses a multimodal data collection approach 758 that includes both paper (e.g., neuropsychological battery) and electronic sources (e.g., 759 participant and study partner questionnaires). Paper sources are scanned and entered in REDCap, an electronic data capture and management system offered through the University of 760 761 Miami Miller School of Medicine. Access to REDCap via password and restricted to CCBH Data 762 Core staff. Participant and study partner questionnaires are distributed via email to individual study participants and accessed via REDCap-generated guestionnaire link, with completed 763 questionnaires saved directly in REDCap. Select parameters from machine (e.g., OCT, Zeno 764 765 Walkway) and lab and imaging (e.g., MRI, PET) reports are entered in REDCap with full reports 766 stored on University of Miami approved and backed-up shared drives.

767

768 REDCap is managed by the University of Miami Biomedical and the Health Research 769 Informatics Core, a secure, private cloud and isolated network infrastructure. This isolated 770 health network is protected by an independent firewall; remote access is provided by a Virtual Private Network (VPN). Data security is assured by Virtual Routing Forwarding (VRF); 2Factor 771 VPN authentication; 10 Gbps Juniper Firewall; Web Proxy Security; Load Balancer; Dell XC 772 Web-Scale Converged Appliances running Windows Hyper-v with Azure; Desktop Virtualization 773 774 with Desktop connections; and Disaster Recovery. The VRF is an isolated, protected network perimeter that enforces the necessary security and compliance restrictions needed to protect 775 776 data from external threats.

777

All precautions to protect the integrity of the data are taken and any unauthorized access will be
 reported to the University of Miami Institutional Review Board. To minimize risk, all materials are

32

kept in locked file cabinets (paper sources) and secure servers (electronic sources), which are
only available to the research team members. Data shared outside of the study team is deidentified prior to distribution using a unique participant code identifier. The CCBH laboratory
has restricted access to personnel. Samples collected are processed immediately and sent out
for analysis. Excess blood is stored in the CCBH laboratory refrigerator and freezers indefinitely,
according to current standard operating procedures.

786

787 Safety considerations

788

This observational cohort study does not meet the definition of a clinical trial and an external 789 790 Data Safety Monitoring Board is not required. Despite all precautions, medical complications 791 may occur and any adverse events will be reported to the IRB. These include not only physical 792 injury, but also possible psychological, social or economic harm, discomfort, inconvenience, or breach of confidentiality. To minimize risk, all study materials are kept in locked file cabinets and 793 794 only available to investigators and research personnel associated with the study. In the event of 795 an adverse effect, medical personnel are available with access to an emergency room. For the 796 standard clinical examinations, there are minimal to no risks associated with testing. The main 797 risk is loss of privacy, and every precaution is taken to ensure confidentiality. We are sensitive to disclosure of examination results; this will be performed in private with feedback including 798 medical referrals and follow-up provided to participants. All precautions to protect the integrity of 799 800 the data repository and registry will be made and any unauthorized access will be reported to the University of Miami Miller School of Medicine IRB. 801

802

Following the feedback session, participants can be referred to CCBH clinical practices for clinical evaluation and follow-up. There are no inherent risks associated with the physical,

33

805 neurological, or psychiatric exams other than discovering a condition that was not previously
806 known. Specific HBI procedures have specific risks as described below:

807

To reduce the risk of loss of balance and falling, functional testing will be performed by 808 809 research staff trained by a physical therapist with advanced expertise (DPT). There is a 810 potential risk in self-collected saliva, of coming into contact with the stabilizing fluid located in the test tube. Users may experience eye and/or skin irritation. User 811 812 instructions provide warning and how to obtain guidance for handling accidental contact with the stabilizing fluid. The potential risks of blood drawing may occasionally include 813 814 pain, bruising, fainting, or a small infection at the puncture site. Indications of procedure to follow in case of any of these will be provided to the participants. 815

816

MRI scanning involves the use of a magnet and radio frequency energy. Individuals who 817 have implanted devices, such as pacemakers, certain aneurysm clips, shrapnel, 818 819 defibrillators, cochlear/ear devices, deep brain stimulators, spinal cord monitoring 820 devices, or metal in the eye or skull are at risk. Therefore, before the procedure, each 821 candidate will be pre-screened for presence of absolute and relative contraindications. 822 Presence of absolute contraindications will disgualify participants from the MRI 823 procedure, while presence of relative contraindications will warrant a careful weighting of 824 risks against benefits for the participant. Those cleared for the procedure will be instructed to remove all metallic objects prior to entering the MRI room. In the case of a 825 826 medical emergency, trained personnel will follow their respective MRI Emergency 827 Procedures Protocol, which entails calling 911, transferring the participant out of the magnetic field area, and providing basic life support by the radiologist, if necessary, until 828 829 emergency service arrives. Procedures are also described for situations when an

34

830

831

emergency stop is required, a magnet emergency occurs, or other unexpected events (e.g., power outages) emerge.

832

The risks associated with PET scans will be discussed with the participants prior to them 833 834 undertaking the procedure. They include exposure to a radioactive ligand and local site 835 injection reactions. The most common adverse reactions are injection site erythema (1.7%), injection site irritation (1.1%) and injection site pain (3.4%). It is not known 836 837 whether Neuraceq can cause fetal harm (Pregnancy Category C) so women of reproductive potential will be required to have a pregnancy test (paid for by the study) to 838 839 assess pregnancy status prior to administration. Pregnant women are excluded from 840 participating in this component of the study. PET compounds, such as Florbetaben F18 (Neuraceq), use small amounts of radiation to generate images. Everyone receives a 841 small amount of unavoidable radiation each year. Some of this radiation comes from 842 843 space and some from naturally occurring radioactive forms of water and minerals. Each 844 Florbetaben F18 scan has a radiation dose equivalent to about 1.6 years' worth of natural radiation (approximately 5.8 millisievert or mSv). The use of a CT scan to 845 846 calculate attenuation correction for reconstruction of Neuraceq images (as done in 847 PET/CT imaging) will add radiation exposure. Diagnostic head CT scans using helical scanners administer an average of 2.2 ± 1.3 mSv effective dose (CRCPD Publication E-848 849 07-2, 2007). The actual radiation dose is operator and scanner dependent. Thus, the total combined radiation exposure from Neuraceg administration and subsequent scan 850 on a PET/CT scanner is estimated to be 8 mSv. 851

- 852
- 853
- 854
- 855

35

856 Sample size/power and planned statistical analyses

857

Sample size and power. HBI encompasses multiple aims (described further above), and
therefore varying statistical approaches and sample sizes will be involved depending on the
research question at hand. Diagnostics will be conducted to assess for non-linearity, missing
data, and other issues (e.g., multicollinearity) and adjustments will be made to the analyses as
necessary (e.g., multiple imputation).

863

864 The HBI was originally built off and thus devised to accommodate planned analyses for a grantfunded study on Multicultural Community Dementia Screening" (MCS) (NIH/NIA 865 R01AG040211). The MCS study was designed to evaluate transition in cognitive status 866 according to NIA-AA stages. For that study, we calculated that we would need a sample of 500 867 868 participants to give us a representative sample across racial and ethnic strata, sex, and NIA-AA stages I-IV. This works out to approximately 100 individuals for each of the 5 cognitive states 869 870 (e.g., normal cognition, subjective cognitive decline, etc.). To maintain 80% power for Black participants based on the desired racial/ethnic distribution (80% White, 20% Black; 35% 871 872 Hispanic), we will need at least 100 (20% with 95% C.I. 82 - 118) for a minimum prevalence rate of 28%. 873

874

Statistical analyses. The MCS study aims to detect longitudinal decline and transition across
NIA-AA stages using the baseline measures and develop a predictive model for identifying
individuals at high risk to transition between NIA-AA stages. Several statistical approaches will
be used to characterize longitudinal changes within a multicultural community-based cohort to
determine whether baseline demographic, functional, genetic, and medical characteristics
predict changes in cognition from baseline during annual evaluations. The progression of
prevalence rate changes from baseline to 12, 24, and 36 months of follow-up will be calculated with

36

95% CI using Clopper-Pearson interval (113). During planned follow-up, we estimate that
approximately 5% of cognitively normal participants aged 55-65, 10% of cognitively normal
participants aged 65-75, and 40% of cognitively normal participants aged 75+ at baseline will
transition to some form of cognitive impairment (114). We conservatively estimate a 15%
attrition rate based on published rates (115) – this is higher than our experience with prior
cohorts (~10%).

888

For longitudinal cognitive decline and transition across NIA-AA stages, we will use generalized 889 890 linear mixed effect (GLME) models to compare the baseline diagnostic groups on rate of decline in cognitive performance. GMLE models also allow the assessment of change in continuous 891 outcomes measure at multiple time points, modeling both fixed and random effects, and 892 893 flexibility handling missing data. The impact of baseline cognitive status on the cumulative odds 894 of being cognitively impaired (SCI, MCI and ADRD) versus being cognitive normal in the end of last follow-up will be assessed by the proportional-odds cumulative (POC) logit model, 895 896 commonly used for ordinal data. Under the proportional odds assumption, we assumed that the effect estimated between each pair of outcomes across two response levels are the same so we 897 898 will test the proportional odds assumption for model appropriateness. Covariates such as SES, 899 demographics, biomarker, imaging, and genetic risk factors for identifying observed transitions will 900 be tested and evaluated in the model. Since there are a large number of variables will be involved in 901 the model, we will apply Benjamini and Hochberg procedure to account for the multiple 902 comparison issue to keep the type I error α =.05 (116). For assessing NIA-AA stage transitions over the study period (e.g., normal to SCI, normal to MCI, MCI to mild ADRD), we will use the 903 ordinal logistic Markov chain transition model, an extension of the POC model, which considers 904 905 intermediary transition for equal space data with more than two response variables with the 906 assumption that the conditional distribution of the outcome at time point T only depends on the state at previous time point T-1. A stepwise regression with covariates sex, racial/ethnic group 907

37

908 and age will be used to select the predictive covariates from longitudinal cognitive, fluid, genetic, 909 and imaging biomarker results to predict the longitudinal decline and transition across NIA-AA stages. The final model will include all significant (p-value<.05) independent variables. 910 interactions, and all pre-retained variables such as sex (to obtain the sex-adjusted odds ratios 911 912 and 95% CI, along with risk differences) and age effect in cognitive impairment. We will vary 913 covariance matrices to derive the best model with the lowest Bayesian Information Criterion 914 (BIC). If models do not converge, we will use generalized estimating equation (GEE) with 915 covariance matrices.

916

Understanding how risk factors work together and developing a predictive model for identifying 917 high-risk individuals is one important aim of this proposal (117, 118). However, age is not only 918 919 the strongest risk factor for ADRD but is also the strongest risk factor for death. Since the 920 mortality rate in this cohort is not ignorable, we may consider a discrete time competing risk 921 model via generalized additive regression. It is clear that the conversion risks from normal to 922 MCI and from MCI to ADRD increases sharply after the age 80. Thus, once all the coefficients and functions of the regression models are estimated, we will construct the transition probability 923 924 matrix considering age among the cognitively normal, cognitively impaired (MCI/ADRD), and at 925 death. We will also test for back conversion from MCI/ADRD to normal and from ADRD to MCI. 926 This probability matrix can then be used to estimate the future conversion risk for an individual as well as the future composition of normal, MCI, and ADRD participants in a group of 927 928 participants. Cognitive progression models can be constructed by using the multi-state Markov models with two competing absorbing states: MCI/ADRD and death, this is the commonly used 929 930 model with three states: normal, MCI/ADRD and death, so the transition probability matrix are 931 permitted from normal to MCI/ADRD, MCI/ADRD to death, normal to death, and MCI/ADRD to 932 normal (117, 118).

38

934 Ethical considerations and declarations

935

HBI has been approved by the University of Miami Miller School of Medicine Institutional Review

937 Board. Participants will provide informed consent at baseline and will be re-consented as

938 needed with protocol changes.

939

940 Timeline of the study

941

HBI began recruiting participants in 2022. As of September 21, 2023, 156 participants have completed their baseline visit and a growing number of participants are being seen for their first follow-up visit. Enrolled participants are expected to be seen annually until the point at which they display moderate to severe ADRD symptoms and are no longer able to complete the evaluations, at which point they will be discontinued from the study. HBI is designed to be an ongoing, longitudinal cohort that recruits at least 500 participants and then maintains that sample size by refreshing the cohort to counteract any participant drop out.

949

950 **DISCUSSION**

951

HBI is planned as an ongoing, longitudinal observational cohort study of brain health among 500 952 racially/ethnically diverse participants with no or mild cognitive impairment living in the South 953 954 Florida region. It is differentiated from other cohorts of brain health and ADRD in its deep phenotyping and collection of a host of novel predictors (e.g., neighborhood social determinants 955 of health, epigenetics) of risk for and resilience against ADRD and cognitive decline measured 956 957 over the life course, in characterizing and validating new ADRD (e.g., neurobehavioral) 958 biomarkers, and in employing unique approaches and methods (e.g., machine learning, transdisciplinary, exposome, etc.). Standardized questionnaires and assessments used across 959

39

multiple grant funded projects ensures comparability of measures and pooling of data that will
permit high powered studies, which is particularly important for studies such as those examining
effect measure modification that require large sample sizes. The cohort study will be significant
in not only identifying modifiable factors that can be targeted via interventions to promote brain
health and reduce ADRD risk, but also in its creation of a data and biospecimen repository, that
can be shared in collaboration with the larger research community.

966

967 HBI's limitations include a potential lack of generalizability of findings to certain communities 968 and groups. Commonly, research volunteers tend to be more educated and less diverse than 969 the general population and socioeconomically disadvantaged populations can be harder to retain in longitudinal cohort studies. Targeted recruitment efforts will be made to ensure a 970 971 diverse group of participants are enrolled, including regular talks and events (e.g., health 972 screenings) in communities that are representative of the diversity HBI aims to achieve. CCBH 973 has begun building relationships with diverse communities in the South Florida area and plans 974 to expand upon and support these relationships to develop an awareness of CCBH and to develop trust with local communities. Various retention efforts will be employed such as regular 975 976 newsletters, telephone follow-up calls in between the annual visits, and sending birthday cards 977 to participants. Transportation costs are covered for individuals who have no other means of traveling to CCBH to complete their HBI visits. 978

979

The expansive nature of the data collected at each annual visit places some burden on participants' time, which could also affect retention. The CCBH team regularly weighs the utility of the data being collected in fulfilling HBI's goals against participant burden. When needed, adjustments are and will be made to questionnaire forms, assessments, or the order of visit activities to minimize burden and/or incorporate new research questions.

40

986 The goal of recruiting and maintaining a steady cohort of 500 participants involves forethought. 987 CCBH works to ensure it has the resources, staff, and scheduling time required to achieve this recruitment goal, including availability of ample facility spaces to conduct the visits and 988 individuals who are cross-trained in multiple assessments to cover staff who are out of the 989 990 office. The structure and timing of visits are designed to ensure the maximum number of 991 participants can be seen over a given week, and a Clinical Trial Management System will be implemented to efficiently track all visits, reminder calls to participants, schedule staff time, 992 993 supplies, and the like. New staff and additional research space will be acquired as needed to 994 meet the recruitment sample size goals.

995

996 Findings from HBI will be disseminated broadly in a variety of formats. Results will be presented 997 at academic conferences; at community events; and at local, national, and international 998 seminars/presentations; and findings will be published in peer-reviewed journals. Newsworthy 999 findings will be broadcast via press releases to the University of Miami media office and local 900 and national print and other media sources. In addition, highlights from the study will be 901 included in our regular newsletter for participants.

1002

In summary, HBI is poised to make substantial contributions to the growing field of research on
brain health and risk and resilience factors associated with ADRD. The data collected will lead
to breakthroughs in developing new diagnostics and therapeutics, create comprehensive
diagnostic evaluations, provide the evidence base for precision medicine approaches to
dementia prevention with individualized treatment plans, provide educational and training
opportunities, and create information clearinghouse activities for participants, families,
caregivers, the lay public, health professionals, and policy makers.

41

1011 Author contributions

- 1012 Dr. Besser: Conceptualization, Writing Original Draft Preparation, Writing Review & Editing;
- 1013 Dr. Chrisphonte: Writing Original Draft Preparation, Writing Review & Editing; Dr. Kleiman:
- 1014 Writing Original Draft Preparation, Writing Review & Editing; Dr. O'Shea: Writing Original
- 1015 Draft Preparation, Writing Review & Editing; Dr. Rosenfeld: Writing Original Draft
- 1016 Preparation, Writing Review & Editing; Dr. Tolea: Writing Original Draft Preparation, Writing
- 1017 Review & Editing; Dr. Galvin: Conceptualization, Writing Original Draft Preparation, Writing -
- 1018 Review & Editing, Supervision.

42

1020 Acknowledgements

- 1021 The Healthy Brain Initiative is supported by NIH *R01AG071514, R01AG071514S1,*
- 1022 R01NS101483, R01NS101483S1, RF1AG075901, and R56AG074889. HBI would not be
- 1023 possible without the support of the Comprehensive Center for Brain Health's staff and
- 1024 postdoctoral fellows: Katherine Almonte, Mirza Baig, Andrea Buehler, Yolene Caicedo, Simone
- 1025 Camacho, Gabrielle Czerwonko, Iris Cohen, Shanell Disla, Reem Ezzeddine, Conor Galvin,
- 1026 Gregory Gibbs, Keri Greenfield, Adolfo Henriquez, Mahesh Joshi, Elaine Le, Nicole Mendez,
- 1027 Claudia Moore, Aimee Ortiz, Mary Lou Riccio, Amie Rosenfeld, Ciny Singh, Monica
- 1028 Sonnenberg, Rebecca Smither, Marcia Walker, and Willman Zambrano. Dr. Besser is supported
- by NIH/NIA K01 AG063895, NIH/NIA R21 AG075291, and Alzheimer's Association Research
- 1030 Grant (AARG-21-850963).
- 1031

1032 Competing interests:

- 1033 All authors have completed the ICMJE uniform disclosure form
- 1034 at <u>www.icmje.org/coi_disclosure.pdf</u> and declare: that the submitted work is supported by NIH
- 1035 R01AG071514, R01AG071514S1, R01NS101483, R01NS101483S1, RF1AG075901, and
- 1036 *R56AG074889*; there are no financial relationships with any organizations that might have an
- 1037 interest in the submitted work in the previous three years; and no other relationships or activities
- 1038 that could appear to have influenced the submitted work.

43

1039 **References**

- 1040 1. World Health Organization. Dementia n.d. [Available from: https://www.who.int/news-1041 room/fact-sheets/detail/dementia.
- 1042 2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al.
- 1043 The diagnosis of dementia due to Alzheimer's disease: recommendations from the National
- 1044 Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's
- 1045 disease. Alzheimers Dement. 2011;7(3):263-9.
- 1046 3. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al.
- 1047 Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB
- 1048 Consortium. Neurology. 2017;89(1):88-100.
- 1049 4. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in
 1050 Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.
- 1051 5. Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al.
- Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10(3):362-77.
- 1053 6. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19(4):1598-695.
- 1054 7. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia
- 1055 prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet.
- 1056 2020;396(10248):413-46.
- 1057 8. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al.
- Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-734.
- 1059 9. Montine TJ, Cholerton BA, Corrada MM, Edland SD, Flanagan ME, Hemmy LS, et al.
- 1060 Concepts for brain aging: resistance, resilience, reserve, and compensation. Alzheimers Res 1061 Ther. 2019;11(1):22.
- 1062 10. Wang Y, Pan Y, Li H. What is brain health and why is it important? BMJ.
- 1063 2020;371:m3683.

44

1064 11. Irwin K, Sexton C, Daniel T, Lawlor B, Naci L. Healthy Aging and Dementia: Two Roads 1065 Diverging in Midlife? Front Aging Neurosci. 2018;10:275.

1066 12. Chimthanawala NMA, Haria A, Sathaye S. Non-invasive Biomarkers for Early Detection

1067 of Alzheimer's Disease: a New-Age Perspective. Mol Neurobiol. 2023. doi: 10.1007/s12035-

1068 023-03578-3.

1069 13. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA

1070 Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers

1071 Dement. 2018;14(4):535-62.

1072 14. Jack CR, Jr., Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al.

1073 Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory

1074 Decline Among Individuals Without Dementia. JAMA. 2019;321(23):2316-25.

1075 15. Tan CH, Bonham LW, Fan CC, Mormino EC, Sugrue LP, Broce IJ, et al. Polygenic

1076 hazard score, amyloid deposition and Alzheimer's neurodegeneration. Brain. 2019;142(2):460-

1077 70.

1078 16. Kikukawa T, Abe T, Ataka S, Saito H, Hasegawa I, Mino T, et al. Amyloid deposition and

1079 CBF patterns predict conversion of mild cognitive impairment to dementia. Neurol Sci.

1080 2018;39(9):1597-602.

1081 17. Rentz DM, Mormino EC, Papp KV, Betensky RA, Sperling RA, Johnson KA. Cognitive

resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau

1083 Burden on cognitive performance. Brain Imaging Behav. 2017;11(2):383-90.

1084 18. Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181

1085 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-

1086 positron emission tomography. Alzheimers Dement. 2018;14(8):989-97.

1087 19. Reas ET, Hagler DJ, Jr., White NS, Kuperman JM, Bartsch H, Wierenga CE, et al.

1088 Microstructural brain changes track cognitive decline in mild cognitive impairment. Neuroimage

1089 Clin. 2018;20:883-91.

45

1090 20. Shim G, Choi KY, Kim D, Suh SI, Lee S, Jeong HG, et al. Predicting neurocognitive

1091 function with hippocampal volumes and DTI metrics in patients with Alzheimer's dementia and

1092 mild cognitive impairment. Brain Behav. 2017;7(9):e00766.

1093 21. Vasta R, Augimeri A, Cerasa A, Nigro S, Gramigna V, Nonnis M, et al. Hippocampal

1094 Subfield Atrophies in Converted and Not-Converted Mild Cognitive Impairments Patients by a

1095 Markov Random Fields Algorithm. Curr Alzheimer Res. 2016;13(5):566-74.

1096 22. Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, et al. ATN

1097 profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology.

1098 2019;92(14):e1567-e79.

1099 23. Vos SJB, Duara R. The prognostic value of ATN Alzheimer biomarker profiles in

1100 cognitively normal individuals. Neurology. 2019;92(14):643-4.

1101 24. Cummings J. The National Institute on Aging-Alzheimer's Association Framework on

Alzheimer's disease: Application to clinical trials. Alzheimers Dement. 2019;15(1):172-8.

1103 25. Gauthier S, Zhang H, Ng KP, Pascoal TA, Rosa-Neto P. Impact of the biological

definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about

the role of vascular changes, inflammation, Lewy body pathology? Transl Neurodegener.

1106 2018;7:12.

1107 26. Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, et al.

1108 Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias:

1109 Update and areas of immediate need. Alzheimers Dement. 2019;15(2):292-312.

1110 27. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education

and occupation on the incidence of Alzheimer's disease. JAMA. 1994;271(13):1004-10.

1112 28. Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers.

1113 Alzheimers Res Ther. 2014;6(2):21.

1114 29. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: the

1115 caregiver experience of clinical care. Parkinsonism Relat Disord. 2010;16(6):388-92.

- 1116 30. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia:
- 1117 caregiver burden and unmet needs. Alzheimer Dis Assoc Disord. 2010;24(2):177-81.
- 1118 31. Besser LM, Galvin JE. Perceived burden among caregivers of patients with
- 1119 frontotemporal degeneration in the United States. Int Psychogeriatr. 2018:1-11.
- 1120 32. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules.
- 1121 Neurology. 1993;43(11):2412-4.
- 1122 33. Stanley MPH, Hall KE, Mullally WJ. The Neurologic Exam. Am J Med. 2023;136(7):6381123 44.
- 1124 34. Palmer JL, Coats MA, Roe CM, Hanko SM, Xiong C, Morris JC. Unified Parkinson's
- 1125 Disease Rating Scale-Motor Exam: inter-rater reliability of advanced practice nurse and
- neurologist assessments. J Adv Nurs. 2010;66(6):1382-7.
- 1127 35. S. Fahn RLE. Unified Parkinson's Disease Rating Scale. Recent Developments in
- 1128 Parkinson's Disease. 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p. 153-63,
- 1129 293-304.
- 1130 36. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology.
- 1131 1967;17(5):427-42.
- 37. Galvin JE. Improving the Clinical Detection of Lewy Body Dementia with the Lewy Body
 Composite Risk Score. Alzheimers Dement (Amst). 2015;1(3):316-24.
- 1134 38. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, et al. Cerebral
- blood flow in dementia. Arch Neurol. 1975;32(9):632-7.
- 1136 39. Tolea MI, Heo J, Chrisphonte S, Galvin JE. A Modified CAIDE Risk Score as a
- 1137 Screening Tool for Cognitive Impairment in Older Adults. J Alzheimers Dis. 2021;82(4):1755-68.
- 1138 40. Dunietz GL, Chervin RD, Burke JF, Conceicao AS, Braley TJ. Obstructive sleep apnea
- treatment and dementia risk in older adults. Sleep. 2021;44(9).
- 1140 41. Marinelli JP, Lohse CM, Fussell WL, Petersen RC, Reed NS, Machulda MM, et al.
- 1141 Association between hearing loss and development of dementia using formal behavioural

- audiometric testing within the Mayo Clinic Study of Aging (MCSA): a prospective population-
- based study. Lancet Healthy Longev. 2022;3(12):e817-e24.
- 1144 42. Li QY, Li XM, Hu HY, Ma YH, Ou YN, Wang AY, et al. Associations of Lung Function
- 1145 Decline with Risks of Cognitive Impairment and Dementia: A Meta-Analysis and Systematic
- 1146 Review. J Alzheimers Dis. 2023;92(3):853-73.
- 1147 43. Espeland MA, Newman AB, Sink K, Gill TM, King AC, Miller ME, et al. Associations
- 1148 Between Ankle-Brachial Index and Cognitive Function: Results From the Lifestyle Interventions
- and Independence for Elders Trial. J Am Med Dir Assoc. 2015;16(8):682-9.
- 1150 44. Flanigan PM, Khosravi MA, Leverenz JB, Tousi B. Color Vision Impairment
- 1151 Differentiates Alzheimer Dementia From Dementia With Lewy Bodies. J Geriatr Psychiatry
- 1152 Neurol. 2018;31(2):97-102.
- 1153 45. Colblindor. Color Arrangement Test 2021 [Available from: https://www.color-
- 1154 blindness.com/color-arrangement-test/.
- 1155 46. Berg L. Clinical dementia rating. The British Journal of Psychiatry. 1984;145(3):339-.
- 1156 47. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for
- assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136-9.
- 1158 48. Benedict RH, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-
- 1159 Revised: Normative data and analysis of inter-form and test-retest reliability. The Clinical
- 1160 Neuropsychologist. 1998;12(1):43-55.
- 1161 49. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al.
- 1162 The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.
- 1163 J Am Geriatr Soc. 2005;53(4):695-9.
- 1164 50. Reisberg D, Rappaport I, O'Shaughnessy M. Limits of working memory: The digit digit-
- span. Journal of Experimental Psychology: Learning, Memory, and Cognition. 1984;10(2):203.

- 1166 51. Galvin JE, Chrisphonte S, Cohen I, Greenfield KK, Kleiman MJ, Moore C, et al.
- 1167 Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the
- Lewy body dementia module (LBD-MOD). Alzheimer's & dementia. 2021;17(10):1675-86.
- 1169 52. Butters N, Granholm E, Salmon DP, Grant I, Wolfe J. Episodic and semantic memory: A
- 1170 comparison of amnesic and demented patients. Journal of clinical and experimental
- 1171 neuropsychology. 1987;9(5):479-97.
- 1172 53. Ivanova I, Salmon DP, Gollan TH. The multilingual naming test in Alzheimer's disease:
- 1173 clues to the origin of naming impairments. Journal of the International neuropsychological
- 1174 Society. 2013;19(3):272-83.
- 1175 54. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage.
- 1176 Perceptual and motor skills. 1958;8(3):271-6.
- 1177 55. Galvin JE, Tolea MI, Moore C, Chrisphonte S. The Number Symbol Coding Task: A brief
- 1178 measure of executive function to detect dementia and cognitive impairment. PLoS One.
- 1179 2020;15(11):e0242233.
- 1180 56. Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant
 1181 interview in dementia. Neurology. 2006;67(11):1942-8.
- 1182 57. Agrell B, Dehlin O. The clock-drawing test. 1998. Age Ageing. 2012;41 Suppl 3:iii41-5.
- 1183 58. Wechsler D. Wechsler memory scale-revised. Psychological Corporation. 1987.
- 1184 59. Rahman-Filipiak A, Sadaghiyani S, Davis K, Bhaumik AK, Paulson HL, Giordani B, et al.
- 1185 Validation of the National Alzheimer's Coordinating Center (NACC) Lewy Body Disease Module
- 1186 neuropsychological tests. Alzheimer's & Dementia: Diagnosis, Assessment & Disease
- 1187 Monitoring. 2022;14(1):e12279.
- 1188 60. Cahn-Hidalgo D, Benabou R, Kewin S. Validity, Reliability, and Psychometric properties
- 1189 of Cognivue®, a quantitative assessment of cognitive impairment. The American Journal of
- 1190 Geriatric Psychiatry. 2019;27(3):S212.

1191 61. Zigmond A, Snaith R, Kitamura T. The hospital anxiety and depression scale (HADS).

1192 Acta psychiatr scand. 1983;67(6):361-70.

1193 62. Miller DK, Malmstrom TK, Andresen EM, Miller JP, Herning MM, Schootman M, et al.

- 1194 Development and validation of a short portable sarcopenia measure in the African American
- health project. J Gerontol A Biol Sci Med Sci. 2009;64(3):388-94.
- 1196 63. Wilkins CH, Roe CM, Morris JC. A brief clinical tool to assess physical function: the mini-
- 1197 physical performance test. Arch Gerontol Geriatr. 2010;50(1):96-100.
- 1198 64. Dite W, Temple VA. A clinical test of stepping and change of direction to identify multiple
- 1199 falling older adults. Arch Phys Med Rehabil. 2002;83(11):1566-71.
- 1200 65. Campbell CM RJ, Ciol MA, Shumway-Cook A. The effect of cognitive demand on timed
- 1201 up and go performance in older adults with and without Parkinson disease. Journal of
- 1202 Neurologic Physical Therapy. 2003;27(1):2-7.
- 1203 66. Shumway-Cook A, Brauer S, Woollacott M. Predicting the probability for falls in
- 1204 community-dwelling older adults using the Timed Up & Go Test. Phys Ther. 2000;80(9):896-

1205 903.

- 1206 67. Clark RA, Pua YH, Fortin K, Ritchie C, Webster KE, Denehy L, et al. Validity of the
- 1207 Microsoft Kinect for assessment of postural control. Gait Posture. 2012;36(3):372-7.
- 1208 68. Yeung LF, Cheng KC, Fong CH, Lee WC, Tong KY. Evaluation of the Microsoft Kinect
 1209 as a clinical assessment tool of body sway. Gait Posture. 2014;40(4):532-8.
- 1210 69. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A
 1211 Biol Sci Med Sci. 2007;62(7):722-7.
- 1212 70. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in
- 1213 older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56.
- 1214 71. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global
- clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-95.

Noah AM, Almghairbi D, Moppett IK. Optical coherence tomography in mild cognitive

impairment - Systematic review and meta-analysis. Clin Neurol Neurosurg. 2020;196:106036.

50

1218	73.	Ashraf G, McGuinness M, Khan MA, Obtinalla C, Hadoux X, van Wijngaarden P. Retinal	
1219	imagir	ng biomarkers of Alzheimer's disease: A systematic review and meta-analysis of studies	
1220	using brain amyloid beta status for case definition. Alzheimers Dement (Amst).		
1221	2023;	15(2):e12421.	
1222	74.	Galvin JE, Kleiman MJ, Walker M. Using Optical Coherence Tomography to Screen for	
1223	Cogni	tive Impairment and Dementia. J Alzheimers Dis. 2021;84(2):723-36.	
1224	75.	Camargo M, Pais MV, Bellan AFR, Tahira AC, Dos Santos B, Sant'Ana L, et al. Impact	
1225	of Co	gnitive Demand on Eye Movement Pattern in Patients with Alzheimer's Disease. J	
1226	Alzheimers Dis. 2022;90(1):85-95.		
1227	76.	Tao L, Wang Q, Liu D, Wang J, Zhu Z, Feng L. Eye tracking metrics to screen and	
1228	assess cognitive impairment in patients with neurological disorders. Neurol Sci.		
1229	2020;4	41(7):1697-704.	
1230	77.	Mosimann UP, Muri RM, Burn DJ, Felblinger J, O'Brien JT, McKeith IG. Saccadic eye	
1231	mover	ment changes in Parkinson's disease dementia and dementia with Lewy bodies. Brain.	
1232	2005;	128(Pt 6):1267-76.	
1233	78.	Mueller KD, Hermann B, Mecollari J, Turkstra LS. Connected speech and language in	
1234	mild c	ognitive impairment and Alzheimer's disease: A review of picture description tasks. J Clin	
1235	Exp N	europsychol. 2018;40(9):917-39.	
1236	79.	Verfaillie SCJ, Witteman J, Slot RER, Pruis IJ, Vermaat LEW, Prins ND, et al. High	
1237	amylo	id burden is associated with fewer specific words during spontaneous speech in	
1238	indivic	luals with subjective cognitive decline. Neuropsychologia. 2019;131:184-92.	
1239	80.	Mueller KD, Van Hulle CA, Koscik RL, Jonaitis E, Peters CC, Betthauser TJ, et al.	
1240	Amylc	id beta associations with connected speech in cognitively unimpaired adults. Alzheimers	

1241 Dement (Amst). 2021;13(1):e12203.

72.

1216

- 1242 81. Lagun D, Manzanares C, Zola SM, Buffalo EA, Agichtein E. Detecting cognitive
- 1243 impairment by eye movement analysis using automatic classification algorithms. J Neurosci
- 1244 Methods. 2011;201(1):196-203.
- 1245 82. Gills JL, Bott NT, Madero EN, Glenn JM, Gray M. A short digital eye-tracking
- assessment predicts cognitive status among adults. GeroScience. 2021;43(1):297-308.
- 1247 83. Alzheimer's Disease Neuroimaging Initiative. ADNI 3 2017 [Available from:
- 1248 https://adni.loni.usc.edu/adni-3/.
- 1249 84. Kleiman MJ, Chang LC, Galvin JE. The Brain Health Platform: Combining Resilience,
- 1250 Vulnerability, and Performance to Assess Brain Health and Risk of Alzheimer's Disease and
- 1251 Related Disorders. J Alzheimers Dis. 2022;90(4):1817-30.
- 1252 85. Galvin JE, Kleiman MJ, Chrisphonte S, Cohen I, Disla S, Galvin CB, et al. The
- 1253 Resilience Index: A Quantifiable Measure of Brain Health and Risk of Cognitive Impairment and
- 1254 Dementia. J Alzheimers Dis. 2021;84(4):1729-46.
- 1255 86. Kleiman MJ, Galvin JE. The Vulnerability Index: A weighted measure of dementia and 1256 cognitive impairment risk. Alzheimers Dement (Amst). 2021;13(1):e12249.
- 1257 87. Wilcock D, Jicha G, Blacker D, Albert MS, D'Orazio LM, Elahi FM, et al. MarkVCID
- 1258 cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. Alzheimers Dement.
- 1259 2021;17(4):704-15.
- 1260 88. Lu H, Kashani AH, Arfanakis K, Caprihan A, DeCarli C, Gold BT, et al. MarkVCID
- 1261 cerebral small vessel consortium: II. Neuroimaging protocols. Alzheimers Dement.
- 1262 2021;17(4):716-25.
- 1263 89. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature
- and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update.
- 1265 Acta Neuropathol. 2010;119(1):1-4.

52

1266 90. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al.

1267 Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

1268 Brain. 2011;134(Pt 9):2456-77.

- 1269 91. Galvin JE. Prevention of Alzheimer's Disease: Lessons Learned and Applied. J Am
- 1270 Geriatr Soc. 2017;65(10):2128-33.
- 1271 92. Galvin JE. Advancing personalized treatment of Alzheimer's disease: a call for the N-of-1
- 1272 trial design. Futur Neurol. 2018;13(3):151-60.
- 1273 93. Academy of Medical Sciences. Stratified, personalised or P4 medicine: a new direction
- 1274 for placing the patient at the centre of healthcare and health education. 2015.
- 1275 94. Li QY, Tang BH, Wu YE, Yao BF, Zhang W, Zheng Y, et al. Machine Learning: a New

1276 Approach for Dose Individualization. Clin Pharmacol Ther. 2023. doi: 10.1002/cpt.3049.

1277 95. Devi G. A how-to guide for a precision medicine approach to the diagnosis and

treatment of Alzheimer's disease. Front Aging Neurosci. 2023;15:1213968.

- 1279 96. Adewale BA, Coker MM, Ogunniyi A, Kalaria RN, Akinyemi RO. Biomarkers and Risk
- 1280 Assessment of Alzheimer's Disease in Low- and Middle-Income Countries. J Alzheimers Dis.
- 1281 2023. doi: 10.3233/JAD-221030.
- 1282 97. Kleiman MJ, Ariko T, Galvin JE, Alzheimer's Disease Neuroimaging I. Hierarchical Two-
- 1283 Stage Cost-Sensitive Clinical Decision Support System for Screening Prodromal Alzheimer's
- 1284 Disease and Related Dementias. J Alzheimers Dis. 2023;91(2):895-909.
- 1285 98. Kleiman MJ, Barenholtz E, Galvin JE, Alzheimer's Disease Neuroimaging I. Screening
- 1286 for Early-Stage Alzheimer's Disease Using Optimized Feature Sets and Machine Learning. J
- 1287 Alzheimers Dis. 2021;81(1):355-66.
- 1288 99. Centers for Disease Control and Prevention. Exposome and Exposomics 2022
- 1289 [Available from: https://www.cdc.gov/niosh/topics/exposome/default.html.

- 1290 100. University of Wisconsin School of Medicine and Public Health. 2015 Area Deprivation
- 1291 Index v2.0 [Available from: https://www.neighborhoodatlas.medicine.wisc.edu/.
- 1292 101. U.S. Department of the Interior. U.S. Geological Survey Landsat Missions [Available
- 1293 from: https://landsat.usgs.gov/.
- 1294 102. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science.
- 1295 2001;293(5532):1068-70.
- 1296 103. Li S, Hursting SD, Davis BJ, McLACHLAN JA, Barrett JC. Environmental exposure, DNA
- 1297 methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Annals of
- the New York Academy of Sciences. 2003;983(1):161-9.
- 1299 104. Robertson KD. DNA methylation and human disease. Nature Reviews Genetics.
- 1300 2005;6(8):597-610.
- 1301 105. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
- 1302 ageing. Nat Rev Genet. 2018;19(6):371-84.
- 1303 106. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol.
- 1304 2013;14(10):R115.
- 1305 107. McCrory C, Fiorito G, Hernandez B, Polidoro S, O'Halloran AM, Hever A, et al.
- 1306 Association of 4 epigenetic clocks with measures of functional health, cognition, and all-cause
- 1307 mortality in The Irish Longitudinal Study on Ageing (TILDA). bioRxiv. 2020.
- 1308 doi: https://doi.org/10.1101/2020.04.27.063164
- 1309 108. Bell CG, Xia Y, Yuan W, Gao F, Ward K, Roos L, et al. Novel regional age-associated
- 1310 DNA methylation changes within human common disease-associated loci. Genome Biol.
- 1311 2016;17(1):193.
- 1312 109. Zheng Y, Habes M, Gonzales M, Pomponio R, Nasrallah I, Khan S, et al. Mid-life
- 1313 epigenetic age, neuroimaging brain age, and cognitive function: coronary artery risk
- development in young adults (CARDIA) study. Aging (Albany NY). 2022;14(4):1691-712.

- 54
- 1315 110. Nilsson E, Jansson PA, Perfilyev A, Volkov P, Pedersen M, Svensson MK, et al. Altered
- 1316 DNA methylation and differential expression of genes influencing metabolism and inflammation
- in adipose tissue from subjects with type 2 diabetes. Diabetes. 2014;63(9):2962-76.
- 1318 111. Benton MC, Johnstone A, Eccles D, Harmon B, Hayes MT, Lea RA, et al. An analysis of
- 1319 DNA methylation in human adipose tissue reveals differential modification of obesity genes
- before and after gastric bypass and weight loss. Genome biology. 2015;16:1-21.
- 1321 112. Johnson ND, Conneely KN. The role of DNA methylation and hydroxymethylation in
- immunosenescence. Ageing Res Rev. 2019;51:11-23.
- 1323 113. Galvin JE. The Quick Dementia Rating System (Qdrs): A Rapid Dementia Staging Tool.
- 1324 Alzheimers Dement (Amst). 2015;1(2):249-59.
- 1325 114. Defranceso M, Schocke M, Messner HJ, Deisenhammer EA, Hinterhuber H, Marksteiner
- 1326 J, et al. [Conversion from MCI (Mild Cognitive Impairment) to Alzheimer's disease: diagnostic
- 1327 options and predictors]. Neuropsychiatr. 2010;24(2):88-98.
- 1328 115. Lacey RJ, Jordan KP, Croft PR. Does attrition during follow-up of a population cohort
- 1329 study inevitably lead to biased estimates of health status? PLoS One. 2013;8(12):e83948.
- 1330 116. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate a Practical and
- 1331 Powerful Approach to Multiple Testing. J R Stat Soc B. 1995;57(1):289-300.
- 1332 117. Salazar JC, Schmitt FA, Yu L, Mendiondo MM, Kryscio RJ. Shared random effects
- 1333 analysis of multi-state Markov models: application to a longitudinal study of transitions to
- 1334 dementia. Stat Med. 2007;26(3):568-80.
- 1335 118. Jackson CH. Multi-state models for panel data: the msm package for R. J Stat Softw.1336 2011;38(8):1-29.
- 1337 119. Hollingshead AA. Four-factor index of social status. Yale University, New Haven, CT1338 1975.

1339	120.	Li MJ, Black DS, Garland EL. The Applied Mindfulness Process Scale (AMPS): A	
1340	process measure for evaluating mindfulness-based interventions. Pers Individ Dif. 2016;93:6-		
1341	15.		
1342	121.	Liu X, Morris MC, Dhana K, Ventrelle J, Johnson K, Bishop L, et al. Mediterranean-	
1343	DASH	I Intervention for Neurodegenerative Delay (MIND) study: Rationale, design and baseline	
1344	characteristics of a randomized control trial of the MIND diet on cognitive decline. Contemp Cli		
1345	Trials. 2021;102:106270.		
1346	122.	Galvin JE, Tolea MI, Rosenfeld A, Chrisphonte S. The Quick Physical Activity Rating	
1347	(QPAR) scale: A brief assessment of physical activity in older adults with and without cognitive		
1348	impairment. PLoS One. 2020;15(10):e0241641.		
1349	123.	Galvin JE, Tolea MI, Chrisphonte S. The Cognitive & Leisure Activity Scale (CLAS): A	
1350	new measure to quantify cognitive activities in older adults with and without cognitive		
1351	impairment. Alzheimers Dement (N Y). 2021;7(1):e12134.		
1352	124.	Scheim AI, Bauer GR. The Intersectional Discrimination Index: Development and	
1353	valida	tion of measures of self-reported enacted and anticipated discrimination for	
1354	intercategorical analysis. Soc Sci Med. 2019;226:225-35.		
1355	125.	Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health	
1356	Soc Behav. 1983;24(4):385-96.		
1357	126.	Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of functional	
1358	activities in older adults in the community. J Gerontol. 1982;37(3):323-9.		
1359	127.	Boeve BF, Molano JR, Ferman TJ, Lin SC, Bieniek K, Tippmann-Peikert M, et al.	
1360	Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a		
1361	community-based sample. J Clin Sleep Med. 2013;9(5):475-80.		

- 1362 128. Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, et al. DLB
- 1363 fluctuations: specific features that reliably differentiate DLB from AD and normal aging.
- 1364 Neurology. 2004;62(2):181-7.

- 1365 129. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The
- 1366 Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.
- 1367 Neurology. 1994;44(12):2308-14.
- 1368
- 1369

Table 1. Participant questionnaires 1370

Instrument/form	Data collected, examples
Demographics and basic information	Age, gender, race, ethnicity, primary language, years of education, major occupation, retired status, mobility aids, living situation, housing type, study partner relation, address, other state of residence if snowbird (in Florida for winter only)
Hollingshead Index of Social Position (119)	Occupation and education level categories
Participant's family history	Family history of ADRD, Parkinson's disease, stroke, heart disease, diabetes, depression
Advanced care planning	Living will, disability care insurance, etc.
Global health screening	Self-rated physical and mental health, etc.
Participant's medical history	Traumatic brain injury, falls, seizures, high cholesterol, thyroid disease, alcohol and substance use, etc.
Current prescribed and over- the-counter medication	Name, dosage, and frequency of medication
Allergies and diet	Medication allergies, food/environmental allergies, diet restrictions (e.g., gluten free, vegetarian)
Neighborhood questionnaire	Presence and use of parks and greenspaces, crime and safety, presence of sidewalks and grocery stores, trust in neighbors
Depression, Anxiety, and Apathy Assessment (DA ³)	Rating how often over the past 2 weeks "I feel tense and unable to relax", "I sit by and let things happen around me", etc.
Symptom Ratings	Memory and recall, orientation, decision making and problem solving abilities, activities outside the home, function at home and hobby activities, toileting and personal hygiene, behavior and personality changes, language and communication abilities, mood, attention and concentration
Hospital Anxiety and Depression Scale (61)	"I feel tense", "I have worrying thoughts", "I feel slowed down", etc.
Applied Mindfulness Scale (120)	"When faced with a stressful event, I relax my body when I am tense", etc.
The Healthy Brain 9 (HB9)	Compared to 5 years ago, participants rate current ability in "taking care of financial matters, "carrying out my everyday activities", etc.
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet(121)	Over past 3 months, consumption of green leafy vegetables, berries, nuts, beans, etc.

Physical Activity Scale (QPAR) (122)	Days per week and hours per day in various activities such as sitting, walking outside, and light, moderate, and strenuous activities
Cognitive and Leisure Activities (CLAS) (123)	Frequency participating in activities such as socializing with friends, volunteering, exercise, etc.
Autonomic Symptoms Checklist (51)	Over past six months, presence and age of onset of various symptoms such as difficulty swallowing, weight loss, excessive sweating, etc.
Brain Health Over the Lifecourse	Residential addresses at age 10, 25, 40, 65; physical, cognitive, social activity, weight, and diet at ages 25, 40, and 65; lifelong perceived discrimination (124) (e.g., "A doctor, nurse, or other health care provider might treat me poorly"); coping over the lifecourse (125) (e.g., over lifetime, frequency that participant has felt unable to control important things in life).

59

1375 Table 2. Questionnaires completed by study partner

Instrument/form Data collected, examples Age, gender, race, ethnicity, primary language, years of Demographics and basic information education, major occupation, retired status, living situation, relationship to participant, participant's global income, financial costs of caregiving **Functional Activities** Participants ability to carry out activities over past 4 weeks Questionnaire (126) (e.g., keeping track of current events, preparing a balanced meal) Memory and recall, orientation, decision making and problem Symptom Rating (of the participant) solving abilities, activities outside the home, function at home and hobby activities, toileting and personal hygiene, behavior and personality changes, language and communication abilities, mood, attention and concentration Sleep Evaluation (of the Rate participant problems with nighttime sleep and daytime sleepiness in past month, and presence of snoring or vivid participant) dreams/nightmares Mayo Sleep Questionnaire Rate participant sleep behaviors and quality (e.g., "have you (127)ever seen the participant appear to act out his/her dreams while sleeping") Mayo Fluctuation Assesses whether participant has symptoms of cognitive Questionnaire (128) fluctuation (e.g., daytime drowsiness; unclear, disorganized flow of ideas) and frequency, duration, and situations in which it occurs. Neuropsychiatric Inventory Rating for the participant on the presence and severity of (129) symptoms (e.g., delusions, hallucinations, agitation/aggression) Frontal Behavioral Battery Rating for the participant on the presence and severity of symptoms (e.g., difficulty speaking, difficulty swallowing, hit or tried to hit someone, etc.) VHDQ Assess whether in the past 6 months, participant had visual or auditory hallucinations Positive and Negative Ratings on various negative (e.g., "feel stress, strain, or anger Appraisals of Caregiving when dealing with the participant") and positive feelings (e.g., "I am the best person to care for participant") toward caregiving.

1377

1376

Table 3. In-person clinician assessments and procedures

Assessment/Procedure	Visit done/assessedª		
Blood draw	Baseline visit, every follow-up visit		
Neuropsychological evaluation	Baseline visit, every follow-up visit		
	Daseline visit, every follow-up visit		
Clinical Dementia Rating (CDR®)(32)	Baseline visit, every follow-up visit		
Physical Function assessment	Baseline visit, every follow-up visit		
Color Blind Test (45)	Baseline visit, every follow-up visit		
Physical exam	Baseline visit, every follow-up visit		
Neurological exam	Baseline visit, every follow-up visit		
Watch PAT / Sleep study	Baseline visit, every follow-up visit		
Ankle Brachial Index (ABI)	Baseline visit, every follow-up visit		
Pulmonary Function Test (PFT)	Baseline visit, every follow-up visit		
Audiometry Hearing test	Baseline visit, every follow-up visit		
Optical Coherence Tomography (OCT)	Baseline visit, every follow-up visit		
Neurobehavioral markers	Baseline visit, every follow-up visit		
Cognivue (60)	Baseline visit, every follow-up visit		
Magnetic Resonance Imaging (MRI)	Baseline, every two years afterward		
Positron Emission Tomography (PET)	Baseline visit (optional)		
^a IRB-approved modifications to the HBI protocol may add or delete additional			
assessments/procedures and/or their frequency			